Navigation Links
China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2014
Date:11/14/2013

regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company's ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a "reverse merger" with an operating company based in China, as well as general economic conditions; compliance with restrictive debt covenants under our senior convertible notes; and other relevant risks detailed in the Company's filings with the Securities and Exchange Commission in the United States.

This announcement contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars as of and for the periods ending September 30, 2013 were made at the noon buying rate of RMB6.1200 to $1.00 on September 30, 2013 in the City of New York for cable transfers in Renminbi per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. China Cord Blood Corporation makes no representation that the Renminbi or U.S. dollar amounts referred to in this press release could have been or could be converted into U.S. dollars or Renminbi, at any particular rate or at all.

For more information, please contact:China Cord Blood Corporation
Investor Relations Department
Tel
'/>"/>

SOURCE China Cord Blood Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. China Water-Soluble Dietary Fiber Market 2013-2017 Report
2. China Synthetic Resin Industry Report, 2013-2016
3. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
4. Current Trends for Conducting Clinical Trials in China, New Life Science Webinar Hosted By Xtalks
5. China Vanadium Catalyst Market for Sulfuric Acid Production in A New Research Available at MarketReportsChina.com
6. Cellular Biomedicine Group Announces New Product Approved for Market in China and New Exclusive License
7. Silane Coupling Agent Industry 2013 Global & China Development Trend Analysis in a New Study at DeepResearchReports.com
8. Ion-exchange Resin Market 2013 Global & China Trend Analysis in a New Research Available at DeepResearchReports.com
9. Insecticides China News 1307 – New Research Available
10. Bulletproof Security Glass Market in China 2012 - 2016: Worldwide Industry Latest Market Share, Investment Trends, Growth, Size, Trends, Strategy and Forecast Research
11. Humic Acid Industry 2013 China and Global Products Analysis in a New Research Report Available at DeepResearchReports.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
(Date:7/29/2015)... Sanofi, a global and ... quarter of 2015. CEO Olivier Brandicourt ... in different businesses. Watch video interview ... Topics covered in the interview include:  ... Performance drivers - Diabetes ...
(Date:7/29/2015)... MONTREAL , July 29, 2015 /PRNewswire/ - BioAmber Inc. ... Laurin , the Company,s Chief Financial Officer has resigned.  ... former Chief Financial Officer who retired in December 2014, ... search for a permanent successor.     Andy ... Mr. Laurin and ensure a smooth transition.  Andy was ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... 2011 The Jackson Laboratory (JAX), Sackler School of Graduate ... have unveiled a new mammalian genetics track for Ph.D. students. ... both JAX and Tufts. Combining the faculty and resources of ... disease, and the faculty and resources at JAX, with its ...
... EAST BRUNSWICK, N.J., Jan. 7, 2011 Savient Pharmaceuticals, Inc. ... its business activities related to the U.S. launch and commercialization ... the treatment of chronic gout in adult patients refractory to ... track for the promotional launch of KRYSTEXXA in the first ...
... Biopharma, a biopharmaceutical company developing novel and biosuperior ... that the company has entered into a multi-year ... commercialization of novel peptide-based therapeutics. Under ... receive an upfront payment of an undisclosed amount, ...
Cached Biology Technology:The Jackson Laboratory and Tufts University Announce New Ph.D. Track in Mammalian Genetics 2The Jackson Laboratory and Tufts University Announce New Ph.D. Track in Mammalian Genetics 3Savient Pharmaceuticals Provides Business Update 2Savient Pharmaceuticals Provides Business Update 3Savient Pharmaceuticals Provides Business Update 4Savient Pharmaceuticals Provides Business Update 5Savient Pharmaceuticals Provides Business Update 6Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics 2
(Date:7/23/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ) has ... of the Biometrics Industry 2015 " report ... biometrics market is likely to witness significant growth ... the uptake of multiple technologies available. The year ... growth of biometrics in existing applications as well ...
(Date:7/13/2015)... , July 13, 2015 Synaptics Inc. ... human interface solutions, today announced sampling of ClearPad ... display driver integration (TDDI) product targeting smartphones and ... to combine Synaptics , best-in-class touch controller ... driver technology developed in the company,s Japan Design ...
(Date:7/9/2015)... , July 9, 2015  Synaptics ... developer of human interface solutions, today announced ... industry,s first fully hardware encapsulated fingerprint sensor ... authentication technology is literally off the grid, ... biometric matching within the fingerprint sensor to ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... at the University of British Columbia have been able ... much touted antioxidant benefits, tracing valuable compounds to the ... Prof. David Kitts found that the prevailing antioxidants present ... green beans being browned under high temperatures. ...
... PORTLAND, Ore. February 1, 2011. Fact: The ... temperature of the nest: warm nests produce females, cooler nests, ... for about 220 million years, scientists now report that almost ... working to understand how global warming may affect turtle reproduction. ...
... dementia is caused by a breakdown of nerve cells ... (fronto-temporal lobe), which leads to, among other symptoms, a ... forms of frontotemporal dementia is a genetically determined reduction ... Anja Capell and Prof. Christian Haass have now shown ...
Cached Biology News:Roasting coffee beans a dark brown produces valued antioxidants: UBC food scientists 2Turtle populations affected by climate, habitat loss and overexploitation 2Malaria medication may help against 1 type of frontotemporal dementia 2
... Serum • Mouse serum is collected off the clot ... weeks of age. Available Anticoagulants: N-02: ... K2EDTA N-08: Potassium Oxalate N-10: ... ACD N-07: CPD N-09: ...
Recombinant Mouse Wnt-3a...
Contains 100 positive controls for effective screening of HDAC inhibitors by fluorometric method....
... There are at least 20 structurally ... of the TGF-beta superfamily. BMPs were originally ... bone formation. They are also involved in ... organs. BMPs regulate the growth, differentiation, chemotaxis ...
Biology Products: